The past decade has seen the use of imaging in drug discovery explode, with many pharma and biotech companies having made significant investments in the area. In R&D, imaging allows researchers to understand cellular mechanisms, work with model organisms, and study systems-level toxicology and ADME. Medical imaging technology such as PET, CAT, and MRI are also becoming commonplace in clinical trials.
However, many of the images created are never actually used during the decision-making process, for two key reasons:
- Lack of effective, standardized workflows for the imaging technology itself
- Lack of integration of the imaging workflows into the discovery workflow
Because the workflows are not standardized or integrated, images are typically only viewed directly during or just after the experiment has been performed. If gaining access to images together with experimental data and results were easier, this information could be used to better support project decisions, rather than only decisions on an experimental level. Better decisions lead not only to better outcomes, but also provide a greater return of investment from the imaging technologies used.
The challenge lies in implementing simpler and more automated imaging workflows, enabling more scientists to perform image-based research and more project managers at every level to access, compare, and understand the results. With a larger user base, technical tasks such as image upload and storage, image conversion and thumbnail creation, image annotation and result registration need to be simplified, enabling a stronger focus on sciences and ultimately increased scientific output.
Genedata proposes a two-part solution to these challenges, Imagence Software for imaging workflow management and Imagence Consulting to investigate and streamline existing workflows. These solutions can, separately or together, create an imaging workflow that makes the most of existing and future technology investments.